Kensuke Moriwaki

Economics, Econometrics and FinanceSocial SciencesEngineeringMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan”.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan

Value in Health Regional Issues(2024)10.1016/j.vhri.2023.11.003

N/A

0DataRank · unranked

2 citations

Kensuke Moriwaki, Kosuke Morimoto, Xiuting Mo, Takashi Yoshioka, Rei Goto +2 more